CN102482321B - 使用化学控制的氧化还原态重折叠蛋白质 - Google Patents

使用化学控制的氧化还原态重折叠蛋白质 Download PDF

Info

Publication number
CN102482321B
CN102482321B CN201080028756.7A CN201080028756A CN102482321B CN 102482321 B CN102482321 B CN 102482321B CN 201080028756 A CN201080028756 A CN 201080028756A CN 102482321 B CN102482321 B CN 102482321B
Authority
CN
China
Prior art keywords
protein
refolding
buffer
thiol
sulfhydryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080028756.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102482321A (zh
Inventor
J·E·舒尔茨
R·哈特
R·N·基纳三世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Amgen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42710673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102482321(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN102482321A publication Critical patent/CN102482321A/zh
Application granted granted Critical
Publication of CN102482321B publication Critical patent/CN102482321B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201080028756.7A 2009-06-22 2010-06-21 使用化学控制的氧化还原态重折叠蛋白质 Active CN102482321B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21925709P 2009-06-22 2009-06-22
US61/219257 2009-06-22
PCT/US2010/039390 WO2011005488A1 (en) 2009-06-22 2010-06-21 Refolding proteins using a chemically controlled redox state

Publications (2)

Publication Number Publication Date
CN102482321A CN102482321A (zh) 2012-05-30
CN102482321B true CN102482321B (zh) 2015-06-17

Family

ID=42710673

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080028756.7A Active CN102482321B (zh) 2009-06-22 2010-06-21 使用化学控制的氧化还原态重折叠蛋白质

Country Status (15)

Country Link
US (5) US8952138B2 (enExample)
EP (2) EP2445923B1 (enExample)
JP (2) JP5808323B2 (enExample)
KR (1) KR101741859B1 (enExample)
CN (1) CN102482321B (enExample)
AU (1) AU2010270986B2 (enExample)
BR (1) BRPI1011940B8 (enExample)
CA (1) CA2765881C (enExample)
CL (1) CL2011003278A1 (enExample)
EA (1) EA020621B1 (enExample)
IL (1) IL216954A (enExample)
MX (1) MX2011013898A (enExample)
SG (1) SG176963A1 (enExample)
WO (1) WO2011005488A1 (enExample)
ZA (1) ZA201200512B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011013898A (es) 2009-06-22 2012-05-22 Amgen Inc Proteínas replegadas que usan un estado de oxido-reduccion quimicamente controlado.
US8940878B2 (en) 2009-06-25 2015-01-27 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2014128726A2 (en) * 2013-02-22 2014-08-28 Biogenomics Limited Process for high efficiency refolding of recombinant proteins
US10633414B2 (en) * 2015-07-27 2020-04-28 Purdue Research Foundation Tandem folding methods to improve protein folding yield
WO2017040363A1 (en) 2015-09-02 2017-03-09 Merck Sharp & Dohme Corp. A process for obtaining insulin with correctly formed disulfide bonds
KR102579850B1 (ko) * 2016-07-22 2023-09-18 암젠 인크 Fc-함유 단백질의 정제 방법
CN108276470A (zh) * 2017-01-06 2018-07-13 深圳市新产业生物医学工程股份有限公司 细胞裂解液、提取胞内蛋白的方法、制备弓形虫抗原的方法和试剂盒
JP6606284B2 (ja) * 2017-04-10 2019-11-13 花王株式会社 角栓を除去する方法
CN119881293A (zh) 2018-03-21 2025-04-25 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
EP4083058A3 (en) * 2018-11-07 2023-01-11 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
FI4263568T3 (fi) 2020-12-18 2025-09-25 Richter Gedeon Nyrt Menetelmät uudelleen laskostuneen fc-peptidifuusioproteiinin puhdistamiseksi
CN115894604B (zh) * 2022-12-16 2024-01-23 康日百奥生物科技(苏州)有限公司 重组蛋白澄清纯化方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004382A1 (en) * 1990-09-05 1992-03-19 Bunge (Australia) Pty. Ltd. Solubilization of proteins in active forms
CN1295580A (zh) * 1998-02-23 2001-05-16 G·D·西尔公司 制造鼠和人内源性血管生成抑制因子的方法
EP1845103A1 (en) * 2006-04-10 2007-10-17 Boehringer Ingelheim Austria GmbH Method for refolding a protein

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4468464A (en) 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
WO1984003711A1 (en) 1983-03-25 1984-09-27 Celltech Ltd A process for the production of a protein
US4468454A (en) 1983-06-10 1984-08-28 E. I. Du Pont De Nemours And Company Antifoggant process
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
GB8508340D0 (en) 1985-03-29 1985-05-09 Creighton T E Production of protein
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
CA1339757C (en) 1987-04-16 1998-03-17 Robert F. Halenbeck Production of purified biologically active, bacterially produced recombinant human csf-1
IL86090A (en) 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
CA1329119C (en) 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
GB8807673D0 (en) 1988-03-31 1988-05-05 Lingner & Fischer Gmbh Novel article
ATE452190T1 (de) 1988-05-13 2010-01-15 Amgen Inc Verfahren zur isolierung und reinigung von g-csf
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5986070A (en) 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
WO1993018136A1 (en) 1992-03-05 1993-09-16 Cytomed, Inc. Process for supporting hematopoietic progenitor cells
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
ATE147753T1 (de) 1993-11-10 1997-02-15 Pfizer Prozess zur rückfaltung von (pro-)chymosin, unter rückführung von harnstoff
US5466377A (en) 1994-01-19 1995-11-14 Grandics; Peter Chromatography media and their uses
IL113497A (en) 1994-04-28 2001-01-11 Amgen Inc Method for controlling metallophosphate precipitation in high cell density fermentations
WO1995032216A1 (en) 1994-05-25 1995-11-30 University Of Nebraska Board Of Regents Biologically active glycoprotein hormones produced in procaryotic cells
EP0832220A1 (en) 1995-06-07 1998-04-01 Amgen Inc. Ob protein compositions and method
EP0909274B1 (en) 1996-01-23 2005-08-10 Ortho-McNeil Pharmaceutical, Inc. Method for purification of erythropoietin binding protein
US5935824A (en) 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US20020052026A1 (en) 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
US6180391B1 (en) 1998-01-28 2001-01-30 Amgen Inc. Highly efficient controlled expression of exogenous genes in e. coli
PL364734A1 (en) 1998-05-19 2004-12-13 Avidex Limited Soluble t cell receptor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2003505471A (ja) 1999-07-21 2003-02-12 アムジエン・インコーポレーテツド Ｖｇｆポリペプチドおよびｖｇｆ関連障害の治療方法
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU2001274853B2 (en) 2000-05-16 2007-03-22 Bolder Biotechnology, Inc. Methods for refolding proteins containing free cysteine residues
US7153669B2 (en) 2000-09-05 2006-12-26 Amgen Inc. Nucleic acids encoding MK61 receptors
JP2005505494A (ja) 2001-02-23 2005-02-24 イミュネックス・コーポレーション 活性タンパク質の回収増加
US6972327B1 (en) 2001-05-08 2005-12-06 Immunex Corporation Regeneration of chromatography material
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
ITMI20012345A1 (it) 2001-11-08 2003-05-08 Internat Ct For Genetic En Gin Procedimento per la produzione di interferone alfa di grado terapeutico
SI21102A (sl) 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
AU2002345829A1 (en) 2002-06-24 2004-01-06 Dr. Reddy's Laboratories Ltd. Process for preparing g-csf
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
ES2359562T3 (es) 2002-12-20 2011-05-24 Amgen, Inc. Agentes de unión que inhiben miostatina.
US7083948B1 (en) 2002-12-24 2006-08-01 Immunex Corporation Polypeptide purification reagents and methods for their use
EP1449848A1 (en) 2003-02-20 2004-08-25 GBF German Research Centre for Biotechnology Method for the production of cystine-knot proteins
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
EP1687328B1 (en) 2003-10-24 2010-03-31 Amgen, Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
EP1711512B1 (en) 2004-01-30 2012-01-11 Amgen Inc. Process for purifying proteins
ATE516349T1 (de) 2004-02-04 2011-07-15 Novo Nordisk As Verfahren zur rückfaltung von säuger- glycosyltransferasen
WO2005092914A1 (en) 2004-03-22 2005-10-06 Blue Mountain Technology Development Lab Process for promoting proper folding of human serum albumin using a human serum albumin ligand
JP4959566B2 (ja) 2004-08-19 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド トランスホーミング増殖因子βファミリータンパク質の折りたたみ
FR2874318B1 (fr) 2004-08-19 2006-11-24 Oreal Utilisation en cosmetique de composes polysaccharidiques amphoteres a chaine(s) polymerique(s) cationique(s)
DE102004041639A1 (de) 2004-08-27 2006-03-02 Bioceuticals Arzneimittel Ag Verfahren zur Gewinnung von biologisch aktivem humanen G-CSF aus Inclusion Bodies
DK1797127T3 (en) 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
US7435804B2 (en) 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b
AU2005299716B2 (en) 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
DK1828239T3 (da) 2004-12-10 2011-12-19 Zymogenetics Inc FGF18-produktion i prokaryote værter
ES2579758T3 (es) 2005-01-28 2016-08-16 Zymogenetics, Inc. Preparaciones homogéneas de IL-31
US20080171857A1 (en) 2005-03-17 2008-07-17 Uma Devi Komath Process for the Purification of Recombinant Granulocyte-Colony Stimulating Factor
US7344962B2 (en) 2005-06-21 2008-03-18 International Business Machines Corporation Method of manufacturing dual orientation wafers
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007059494A2 (en) 2005-11-14 2007-05-24 Amgen, Inc. Thermally insulated apparatus for liquid chromatographic analysis
CA2632519A1 (en) 2005-12-06 2007-07-05 Amgen Inc. Polishing steps used in multi-step protein purification processes
US20080032343A1 (en) 2005-12-22 2008-02-07 Genentech, Inc. Recombinant Production of Heparin Binding Proteins
US7612273B2 (en) * 2006-03-20 2009-11-03 Roland Corporation Electronic percussion instrument
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
KR101520105B1 (ko) 2006-07-14 2015-05-21 제넨테크, 인크. 재조합 단백질의 리폴딩
WO2008011132A2 (en) 2006-07-21 2008-01-24 Amgen, Inc. Rupture valve
MX2009008104A (es) 2007-02-02 2009-08-07 Amgen Inc Hepcidina, antagonistas de hepcidina y metodos de uso.
WO2008097829A2 (en) 2007-02-02 2008-08-14 Neose Technologies, Inc. Large scale production of eukaryotic n-acetylglucosaminyltransferase i in bacteria
WO2008096370A2 (en) 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
US20080214795A1 (en) 2007-02-14 2008-09-04 Amgen Inc. Method of isolating antibodies by precipitation
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
JP2011514161A (ja) 2008-02-29 2011-05-06 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 免疫グロブリン組成物およびその製造方法
CN110372792A (zh) 2008-06-25 2019-10-25 艾斯巴技术-诺华有限责任公司 抑制vegf的稳定和可溶的抗体
MX2011013898A (es) * 2009-06-22 2012-05-22 Amgen Inc Proteínas replegadas que usan un estado de oxido-reduccion quimicamente controlado.
US8940878B2 (en) * 2009-06-25 2015-01-27 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
TWI708052B (zh) 2011-08-29 2020-10-21 美商安美基公司 用於非破壞性檢測-流體中未溶解粒子之方法及裝置
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
KR20150140294A (ko) 2013-03-15 2015-12-15 암젠 인코퍼레이티드 사람 대상에서 미오스타틴 길항작용
US9632095B2 (en) 2014-12-01 2017-04-25 University Of Delaware Device and method for determining reaction kinetics
US9704239B1 (en) 2016-09-02 2017-07-11 Amgen Inc. Video trigger synchronization for improved particle detection in a vessel

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004382A1 (en) * 1990-09-05 1992-03-19 Bunge (Australia) Pty. Ltd. Solubilization of proteins in active forms
CN1295580A (zh) * 1998-02-23 2001-05-16 G·D·西尔公司 制造鼠和人内源性血管生成抑制因子的方法
EP1845103A1 (en) * 2006-04-10 2007-10-17 Boehringer Ingelheim Austria GmbH Method for refolding a protein

Also Published As

Publication number Publication date
EP3366692A1 (en) 2018-08-29
IL216954A0 (en) 2012-02-29
MX2011013898A (es) 2012-05-22
US20150315232A1 (en) 2015-11-05
JP2012530782A (ja) 2012-12-06
US20100324269A1 (en) 2010-12-23
BRPI1011940B1 (pt) 2021-07-20
CL2011003278A1 (es) 2012-11-09
ZA201200512B (en) 2012-11-28
EP2445923A1 (en) 2012-05-02
JP6026608B2 (ja) 2016-11-16
AU2010270986A1 (en) 2012-01-19
CN102482321A (zh) 2012-05-30
AU2010270986B2 (en) 2014-05-22
BRPI1011940B8 (pt) 2021-08-03
EA201270015A1 (ru) 2012-05-30
KR20120052939A (ko) 2012-05-24
KR101741859B1 (ko) 2017-06-15
US20190055281A1 (en) 2019-02-21
CA2765881A1 (en) 2011-01-13
US9856287B2 (en) 2018-01-02
WO2011005488A1 (en) 2011-01-13
BRPI1011940A2 (pt) 2016-11-22
US8952138B2 (en) 2015-02-10
US20150329586A1 (en) 2015-11-19
JP2016028065A (ja) 2016-02-25
EA020621B1 (ru) 2014-12-30
CA2765881C (en) 2016-08-02
US12269843B2 (en) 2025-04-08
IL216954A (en) 2016-09-29
US20170145049A1 (en) 2017-05-25
EP2445923B1 (en) 2018-09-05
JP5808323B2 (ja) 2015-11-10
SG176963A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
CN102482321B (zh) 使用化学控制的氧化还原态重折叠蛋白质
Qoronfleh et al. Confronting high-throughput protein refolding using high pressure and solution screens
US11345722B2 (en) High pH protein refolding methods
US11053278B2 (en) Tangential flow filtration based protein refolding methods
HK1259915A1 (en) Refolding proteins using a chemically controlled redox state
HK1170245B (en) Refolding proteins using a chemically controlled redox state
HK1170245A (en) Refolding proteins using a chemically controlled redox state

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: California, USA

Patentee after: American Amgen

Address before: California, USA

Patentee before: AMGEN Inc.

CP01 Change in the name or title of a patent holder